David Braun @BraunMDPhD Twitter profile

Pinned Tweet

David Braun

3 years

1/ Happy to share our latest work out today in @Cancer_Cell – a single-cell dissection of the kidney cancer immune microenvironment that uncovers important immune circuitry in advanced disease stages @DanaFarber @DanaFarberNews @harvardmed @broadinstitute

Progressive immune dysfunction with advancing disease stage in renal cell carcinoma

The immune cell changes that occur with advancing disease stage in renal cell carcinoma are incompletely characterized. Braun et al. show that terminally exhausted CD8+ T cells and M2-like tumor-as...

www.cell.com

9

67

246

Last Seen Profiles

@rancaTWICE

@worldwydewayne

@cinemalins

@ThisIsTerentius

@Aono_99

@guerreisons

@Coolmanx5

@HeadlinerPortal

@DailyWeiss

@negativespaceca

@lasuone

@notoriousalerts

@Qlart1Qlart

@gangbye7481603

@BriceIvanovic

@GomedVitoria

@kg_creative

@Abbas_Tweets_

@thalesnemo

@bfigas_

@gregsmirin

@b0tster

@ITVCentral

@geri_doc

@cinemalins

@stw_pdg

@bansyu_kiyomizu

@Sampa_The_Great

@DuzanskyTyler

@takamon20

@ituwakuno

@nao705108169751

@michelleytlock

@taraqur

@rennslyaer

@CustomerCamp

David Braun

@BraunMDPhD

2 years

Officially settling in here @YaleCancer @YaleMed , and I am grateful for the warm welcome! If you are interested in cancer immunotherapy, translational research, genomics, or kidney cancer, please contact me (david.braun @yale .edu). We are hiring at all levels (postgrad, MS, PhD)!

36

67

506

David Braun

@BraunMDPhD

2 years

An exciting but also a bit of a bittersweet announcement - after 8+ amazing years @BrighamMedRes @DanaFarber @harvardmed , I will be starting a new laboratory () @YaleCancer @YaleMed on January 1, 2022 1/n

BraunLab

www.thebraunlab.org

74

28

425

David Braun

@BraunMDPhD

2 years

Out in @NEJM this week, our perspective on some recent outstanding work defining the phenotype of tumor-infiltrating T cells across cancer types, and our thoughts on next steps. Tumor-Infiltrating T Cells — A Portrait | NEJM @YaleCancer @YaleMed

Tumor-Infiltrating T Cells — A Portrait | NEJM

Genetic landscaping and T cells are all the rage when it comes to tumor biology. Put them together and you get a comprehensive view of the T cell in the context of different types of cancer. The au...

www.nejm.org

5

104

409

David Braun

@BraunMDPhD

2 years

And the BraunLab is officially up and running! It may just be culturing some cell lines today, but feels good to be at the bench again. Thanks to my right hand man Nick Schindler and all of the support from @YaleCancer @YaleMed

27

17

302

David Braun

@BraunMDPhD

2 years

Great time chatting about cancer immunotherapy and the importance of physician-scientists with gold medalist @nathanwchen . Thanks for stopping by our lab! @YaleCancer @SmilowCancer @YaleMed

2

56

248

David Braun

@BraunMDPhD

4 years

1/ Excited to share our work on genomic & immune determinants of anti-PD1 response in RCC, presented today #ASCO20 and published @NatureMedicine . Thanks to patients; mentors/collaborators #CathyWu , @DrChoueiri , @shuklasachet , @LabSignoretti , @VanAllenLab

16

60

212

David Braun

@BraunMDPhD

3 years

A very nice overview of some of the differences between anti-CTLA-4 and anti-PD-1 therapies from Dr. Allison #IKCS2021

4

68

193

David Braun

@BraunMDPhD

10 months

Very grateful to @theNCI and @CDMRP for the support to better understand and treat kidney cancer. Importantly, we are hiring postdocs/research scientists with expertise in experimental immunology. If you have extensive experience in immunology, please contact me!

Yale Cancer Center

@YaleCancer

10 months

Congratulations to the lab of @BraunMDPhD ! The team has received approximately $5.75M in funding from @theNCI and @DeptofDefense to investigate the immune microenvironment of renal cell carcinoma. #RCC #kidneycancer #cancerresearch @YaleMed @SmilowCancer

8

7

100

15

25

166

David Braun

@BraunMDPhD

1 year

Thank you @YaleCancer @YaleMed and all my past and present mentors for the support!

Yale Cancer Center

@YaleCancer

1 year

Congratulations to @BraunMDPhD , who has been awarded an American Society for Clinical Investigation ( @the_asci ) Young Physician-Scientist Award. Dr. Braun will attend the AAP/ASCI/APSA Joint Meeting in April. @SmilowCancer @YaleMed @YNHH

2

7

62

16

1

138

David Braun

@BraunMDPhD

4 months

Historic moment form @DrChoueiri , first adjuvant OS benefit in kidney cancer #GU24

1

28

139

David Braun

@BraunMDPhD

2 years

Very grateful to @KidneyCancer for the award, and to the amazing team ( @Chrislabaki1 @LisaHenske @shuklasachet @VanAllenLab @DrChoueiri and others) as we try to better understand and treat this histology and beyond @YaleCancer @SmilowCancer

Kidney Cancer

@KidneyCancer

2 years

⭐️Congratulations to KCA Trailblazer Award winner @BraunMDPhD @YaleCancer @YaleMed ! His research will dissect the #immunobiology of #chromophobe #RCC using single-cell transcriptomics. #kidneycancer

3

8

31

13

129

David Braun

@BraunMDPhD

3 years

1/Excited to see our review on novel immune-based therapies in RCC just published online in @NatRevClinOncol ! . Thanks to everyone who contributed to this work @ZiadBakouny @VanAllenLab #CathyWu and @DrChoueiri

3

28

101

David Braun

@BraunMDPhD

2 months

Excited to share our lab's latest, led by @ReneeSaliby @TJammihal @Chrislabaki1 together with @DrChoueiri @VanAllenLab @ShuklaSachet , and many others, out in @Cancer_Cell Thank you to @YaleCancer @YaleMed for the coverage:

Molecular Subtypes of Advanced Kidney Cancer Matter for Treatment Response

A new study published April 4 in Cancer Cell was led by Yale Cancer Center researchers, who collaborated with investigators nationally to differentiate the

www.yalecancercenter.org

Renee Maria Saliby

@ReneeSaliby

2 months

1/ Thrilled to share that our paper “Impact of RCC molecular subtypes on immunotherapy & targeted therapy outcomes” is now published in @Cancer_Cell Collaborative effort co-led w/ @Chrislabaki1 & @TJammihal under @VanAllenLab @ShuklaSachet @DrChoueiri @BraunMDPhD ‘s mentorship

16

44

160

8

12

83

David Braun

@BraunMDPhD

2 years

Thank you everyone for the very warm welcome to @YaleCancer @YaleMed ! Very excited to be here among such wonderful people.

Müschen Lab

@MuschenLab

2 years

Welcoming @BraunMDPhD as new faculty to our Center. Good times with @DrRoyHerbstYale , Harriet Kluger, @ishizukalab , Dan DiMaio, Mario Sznol and Rick Wilson.

0

2

30

2

3

84

David Braun

@BraunMDPhD

2 years

How it started and how it's going... in KEYNOTE-564, adjuvant pembro seems to be getting better with age in data present by @DrChoueiri at #GU22 . OS not yet significant (immature), but getting closer as time goes on. @ASCO @OncoAlert @kidneycan @KidneyCancer

2

20

81

David Braun

@BraunMDPhD

10 months

PROUD MENTOR MOMENT!! Amazing presentation on biomarkers in non-clear cell RCC, and are of unmet clinical need #kcrs @kidneycan @OncoAlert @YaleCancer @DanaFarber_GU

3

19

74

David Braun

@BraunMDPhD

3 years

Thank you @Cancer_Cell for featuring our work on this month's cover! Please also see the amazing work from @VanAllenLab @MXresearch and from @arihakimi @chirag_msk @GeneCollector aiming to dissect the RCC microenvironment @DanaFarberNews @broadinstitute

2

12

74

David Braun

@BraunMDPhD

2 years

Grateful to join such an outstanding team @YaleCancer @SmilowCancer @YaleMed

The ASCO Post

@ASCOPost

2 years

David Braun, MD, PhD, Joins Prostate and Urologic Cancers Program at Yale Cancer Center @YaleCancer @BraunMDPhD

0

6

49

2

1

66

David Braun

@BraunMDPhD

3 years

Please see our new Perspective on how to utilize scRNA-seq and other single-cell technologies to better understand and to improve cancer immunotherapies. @DanaFarberNews @DanaFarber_GU

NatureRevClinOncol

@NatRevClinOncol

3 years

New Perspective article by Satyen Gohil, Bryan Iorgulescu, David Braun, Derin Keskin & Kenneth Livak now live online: 'Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy' #ImmunoOnc #camicroenv #cagenome

1

21

88

0

18

64

David Braun

@BraunMDPhD

4 months

Very excited to be part of this wonderful group, and looking forward to #GU24 @ASCO @DrChoueiri @bergsa83 @BradMcG04 @mleapman @PatrickKenneyMD @MikeSerzanMD @DrRanaMcKay - any presentations or posters you are particularly looking forward to? @YaleCancer @Yale_Urology @YaleMed

ASCO

@ASCO

4 months

Announcing the #GU24 Featured Voices! Follow along for a range of expert insights & join the discussion using the official hashtag: #GU24 ⤵️ @rccadvocate @BraunMDPhD @ShuchiGulati @sophia_kamran @AmandaNizamMD @RuchikaTalwarMD @drkarinetawagi @dryukselurun @TiansterZhang

2

25

73

6

3

64

David Braun

@BraunMDPhD

10 months

Chromophobe RCC remains an unmet clinical need. In @Cancer_Cell , we review the state of the field and the steps we need to take to make breakthroughs for this disease

1

23

60

David Braun

@BraunMDPhD

2 years

Thank you @AkoyaBio - this will help us understand the determinants of immunotherapy response and resistance in kidney cancer. For any post-docs (experimental or computational), bioinformatic analysts, or research scientists interested in this work and our lab, please DM me!

Akoya Biosciences

@AkoyaBio

2 years

We are pleased to announce that Dr. David Braun ( @braunmdphd ) from @YaleCancer @YaleMed has been selected as the recipient of the Spatial #Multiomics #GrantAward using CODEX! Learn more about this award program and CODEX: #spatialbiology #singlecell

1

7

48

1

6

57

David Braun

@BraunMDPhD

2 years

Honored to have our research featured in this fantastic list of translational GU papers in 2021. Lots more work to do for our patients in 2022!

Toni Choueiri, MD

@DrChoueiri

2 years

12/ ScRNA-seq helps to define immune populations in ccRCC across disease stages and identifies terminally exhausted CD8+ T-cells and M2-like TAMs in advanced ccRCC @Cancer_Cell @BraunMDPhD @justokstreet ; COI: co-senior author

1

11

3

5

56

David Braun

@BraunMDPhD

4 months

Wow. Update from Dr. Tannir @MDAndersonNews presenting 8 year f/u for CM214. For patients who responded to nivo+ipi, half are still responding 8 years later. Also interesting OS for IMDC favorable risk. @OncLive @OncoAlert @urotoday @kidneycan @KidneyCancer

1

22

55

David Braun

@BraunMDPhD

3 years

Tackling an unmet need, @srviswanathan @DanaFarber is furthering our understanding of the molecular underpinnings of translocation RCC #KCRS21

0

10

54

David Braun

@BraunMDPhD

2 years

Sorry I can't be at #KCRS22 , but so proud of @ReneeSaliby and @Chrislabaki1 in my lab and co-mentored by @DrChoueiri . They will both be giving oral presentations today, so Please tune in! @kidneycan @IKCCorg @DanaFarberNews @YaleCancer @YaleMed

1

6

53

David Braun

@BraunMDPhD

1 year

Really excited to share new work from our lab. See excellent Tweetorial from superstar postdoc @ReneeSaliby below @YaleCancer @Yale_Urology @yalepathology @OncoAlert @kidneycan @KidneyCancer

Renee Maria Saliby

@ReneeSaliby

1 year

1/Thrilled to share our work on “Circulating & intratumoral determinants of response to atezo+bev in pts with variant histology or sarco RCC” from #BraunLab @BraunMDPhD & @DrRanaMcKay out in @CIR_AACR W/ @TalalZarif1 @ZiadBakouny @ShahValisha @DrChoueiri & many others

10

16

69

3

7

52

David Braun

@BraunMDPhD

3 years

Many lessons on T cell exhaustion from @EJohnWherry @PennCancer , including how the developmental biology of T cell exhaustion (and why this is important for understanding aPD-1 response), and why continuous PD-1 blockade may not be optimal #SITC21

1

10

52

David Braun

@BraunMDPhD

1 year

Proud mentor moment with superstar @ReneeSaliby presenting her work ar #ASCO23 , co-led by @DrRanaMcKay and many others

1

8

52

David Braun

@BraunMDPhD

3 years

Rising superstar @NazliDizman @YaleIMed taking us through not only the history of microorganisms and cancer, but also exciting recent work on the microbiome and it's relevance for immuno-oncology / RCC #IKCS2021

0

7

50

David Braun

@BraunMDPhD

4 months

Outstanding,insightful discussion by @PBarataMD @ASCO #GU24 . Summary to interpretation to new hypotheses to a practical "how I treat" slide. @OncoAlert @VJOncology @urotoday @kidneycan @KidneyCancer

2

20

50

David Braun

@BraunMDPhD

10 months

Proud mentor alert! @Chrislabaki1 ,comentored with @DrChoueiri and @VanAllenLab , presenting our collaborative chromophobe RCC study, co-led with @LisaHenske and @ShuklaSachet at #kcrs23 @kidneycan @OncoAlert @YaleCancer @DanaFarber @BrighamWomens @MDAndersonNews

0

16

48

David Braun

@BraunMDPhD

9 months

Grateful to be part of this outstanding work led by Drs. Schoenfeld and Kluger @YaleCancer

Journal for ImmunoTherapy of Cancer

@jitcancer

9 months

New #JITC article: Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases @mkmoutafi @BraunMDPhD @DrChoueiri @RimmPathology

0

5

18

0

5

47

David Braun

@BraunMDPhD

1 year

Happy to share this review written with the phenomenal surgeon-scientist Soki Kashima on the changing landscape of immunotherapy for RCC @YaleCancer @SmilowCancer @OncoAlert @kidneycan @IKCCorg @KidneyCancer

0

16

45

David Braun

@BraunMDPhD

3 years

As I start a new phase of my career, I'm appreciative of these words of wisdom on mentorship from @KimrynRathmell @brian_rini @JBrugarolas @montypal @BradLeibovichMD @eric_facs #IKCS2021

0

3

45

David Braun

@BraunMDPhD

2 years

Really enjoyed being on this panel with such a phenomenal group of kidney cancer experts @TiansterZhang @PBarataMD @bilenma @MosheOrnsteinMD @KidneyCancer @kidneycan @IKCCorg

OncLive.com

@OncLive

2 years

WATCH: @BraunMDPhD , of @YaleCancer , explains how biomarkers help to stratify treatment decision-making for patients with RCC. #kcsm #oncology

0

7

20

2

6

44

David Braun

@BraunMDPhD

4 months

An outstanding deep dive in ICI efficacy in variant histology RCC and sarcomatoid differentiation by @DrRanaMcKay @ASCO #GU24 . Take home - these are distinct disease with different biologies,and it will be important to understand and incorporate this info

0

21

43

David Braun

@BraunMDPhD

4 months

Last session of #GU24 @ASCO ! Come join us ( @maughanonc @ZakhariaYousef @sophia_kamran @KidneyCancerDoc ) for a look into the role of radiation, theranostics, and biomarkers in RCC. Also, check out our review on RCC biomarkers here:

3

14

42

David Braun

@BraunMDPhD

4 months

Big day @asco #GU24 . @DrChoueiri presenting the OS data from KN564. First adjuvant trial in RCC history ro show an OS benefit, with nearly 5y followup. Benefit across all subgroups. Supports adjuvant pembro for RCC patients that meet criteria.

2

12

43

David Braun

@BraunMDPhD

2 years

Proud mentor moment! Chris is a rock star (and applying for IM residency for any interested programs). He'll present our collaborative work on chromophobe RCC immunobiology with @LisaHenske @DrChoueiri @shuklasachet @VanAllenLab and many others!

KidneyCAN

@kidneycan

2 years

KCRS22 Oral Abstract Session: @Chrislabaki1 @DanaFarber reports the molecular characterization of the tumor immune microenvironment of chromophobe #RCC and renal oncocytic neoplasms @BraunMDPhD Abstracts: Register: @OncoAlert

0

4

20

1

3

41

David Braun

@BraunMDPhD

1 month

An excellent, balanced discussion of adjuvant therapy in RCC from @brian_rini @tompowles1 @Uromigos . An area of consensus - we need better ways to risk stratification risk of recurrence, including biomarkers #IKCSEU24 @KidneyCancer

0

12

42

David Braun

@BraunMDPhD

3 years

Critical work from @LabGenovese @MDAndersonNews creating new murine models for variant histology and aggressive RCCs, including modeling of 9p21 loss #KCRS21 @kidneycan

1

11

39

David Braun

@BraunMDPhD

1 year

Incredible discussion on therapeutic strategies in urothelial carcinoma by @BourlonMaite , on important abstracts presented by @drenriquegrande Dr. Siefker-Radtke @MDAndersonNews and @shilpaonc , chaired by @NehaVapiwala and @mkbupathi #ASCO23 @ASCOPost @OncoAlert

1

15

38

David Braun

@BraunMDPhD

2 years

What drives the organotropism of RCC metastases? Answering this question will require deep molecular analyses - @DrRanaMcKay @UCSDHealth is doing just that, with an outstanding landscape of molecular features across metastatic sites at #GU22

0

13

37

David Braun

@BraunMDPhD

2 years

Metastatic chromophobe RCC remains an area of tremendous clinical need. In critical work out today, Drs. Henske, Priolo and colleagues @BrighamWomens @harvardmed identify a hypersensitivity to ferroptosis induction in chRCC

Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic depende...

Chromophobe (Ch) renal cell carcinoma (RCC) arises from the intercalated cell in the distal nephron. There are no proven treatments for metastatic ...

www.pnas.org

1

9

37

David Braun

@BraunMDPhD

1 month

@DrYukselUrun providing his framework (with @DrChoueiri input) for metastatic treatment #IKCSEU24 @KidneyCancer

0

9

34

David Braun

@BraunMDPhD

3 years

Jim Allison @MDAndersonNews taking us through the history of immune checkpoint inhibition #IKCS2021

1

3

34

David Braun

@BraunMDPhD

2 years

I am incredibly grateful to @DrJoelKatz for his leadership, mentorship, education, and support over the past decade. He has influenced a generation of physicians, and I am so thankful for all he has done for me personally and for the entire @BrighamMedRes .

Jose Figueroa, MD, MPH

@joefigs2

2 years

The incredible @DrJoelKatz , longtime IM Program Director @BrighamMedRes , is stepping down after 22yrs of wonderful service to generations of @BrighamWomens interns and residents. @DrJoelKatz , thank you for everything you’ve done for us! We owe so much to you. We will miss you!

3

29

224

0

1

35

David Braun

@BraunMDPhD

1 year

Very interesting data from @EbrahimiHedyeh @CityofHope_GU on use of CBM588 with nivo+cabo. Small trial, but a second randomized clinical trial with a different IO-based regimen showing signals of efficacy in RCC #ASCO23 @ASCOPost

2

11

34

David Braun

@BraunMDPhD

8 months

A total superstar. IM programs don't miss out!

Renee Maria Saliby

@ReneeSaliby

8 months

We're doing it #MedTwitter ! I'm Renee Maria Saliby, an IMG from 🇱🇧 & currently 🔬research fellow at @DanaFarber_GU & @YaleCancer Super excited to be applying to #InternalMedicine for #Match2024 Can't wait to connect! More about me⬇️

45

32

284

2

34

David Braun

@BraunMDPhD

4 months

It's starting! Kidney cancer day @ASCO #GU24 @OncoAlert @kidneycan @KidneyCancer

1

8

33

David Braun

@BraunMDPhD

3 years

And that's a wrap. What a fantastic meeting #KCRS21 , then you @kidneycan @DrChoueiri @HHammersMD and all of the incredible patients and advocates

0

4

32

David Braun

@BraunMDPhD

4 years

Honored and excited to be part of such an amazing group, looking to push forward our understand of and therapies for kidney cancer

Dana-Farber News

@DanaFarberNews

4 years

Dana-Farber researchers ( @BraunMDPhD , @DrChoueiri , and Cathy Wu, MD) join the Department of Defense’s new 'Academy of Kidney Cancer Investigators' that will help advance #kidneycancer research to understand resistance & develop new treatments that harness the immune system

1

6

47

2

3

32

David Braun

@BraunMDPhD

3 years

Cytoreductive nephrectomy might positively impact QUALITY of life, even if it doesn't necessarily impact survival. An important talk at #GU21 from Dr. Jodi Maranchie @UPMCHillmanCC

0

19

32

David Braun

@BraunMDPhD

2 years

We are hiring! Looking for an associate computational biologist /bioinformatic analyst to join our lab and work at the interface of genomics and cancer immunotherapy. Pls email/DM me if questions. Official posting at: @YaleMed @DrChoueiri @VanAllenLab

0

18

32

David Braun

@BraunMDPhD

3 years

A phenomenal presentation by @arihakimi at #GU21 highlighting the importance of dissecting the tumor microenvitonemnt in kidney cancer.

1

13

31

David Braun

@BraunMDPhD

2 years

Very nice work from @MattZibelman and @ERPlimackMD at #GU22 , providing further support for excellent disease control with IO+VEGF combos

0

6

31

David Braun

@BraunMDPhD

4 months

Really interesting results from CheckMate 914 part B from @motzermd . NIVO only did not significantly improve DFS in adjuvant setting. Compared to KN564, slightly lower risk population (some T2 any grade, no M1 NED).

2

7

30

David Braun

@BraunMDPhD

1 year

Join me on March 22 for the @sitcancer #LearnACI live virtual Genitourinary Cancers program featuring in-depth education on all aspects of clinical implementation of genitourinary cancers. Register at: @YaleCancer @SmilowCancer @OncoAlert

Advances in Cancer Immunotherapy: A Focus on Genitourinary Cancers

www.sitcancer.org

0

7

29

David Braun

@BraunMDPhD

1 year

Our Center of Molecular and Cellular Oncology is expanding! If you are a laboratory-based physician-scientist or basic scientist, please consider applying and becoming part of this wonderful team @YaleCancer @YaleMed @aacr @asco @ASCOPost @sitcancerECS @IOYIForum

Müschen Lab

@MuschenLab

1 year

Excited to launch the next round of our search for Physician-scientists and Basic Scientists in the Center of Molecular and Cellular Oncology and the Cancer Biology Institute at Yale (). We welcome applicants from diverse backgrounds. Please apply & RT

10

62

439

0

5

29

David Braun

@BraunMDPhD

4 months

Really important work from @crisbergerot aiming to better understand and measure QoL in patients with RCC @ASCO #GU24 @KidneyCancer

1

12

29

David Braun

@BraunMDPhD

3 years

Outstanding keynote from @coussens_lisa from @OHSUKnight at #SITC21 , making the strong case that targeting the myeloid compartment is critical. I think this is very true for RCC, where TAMs likely support T cell dysfunction. Pls see our recent work:

0

9

29

David Braun

@BraunMDPhD

4 years

Cancer doesn’t stop because of #COVID19 . Join me Tuesday, May 19, from 6-8 pm EST to discuss kidney cancer care with thought leaders across the country and @totalhealthmeetings . Register here:

0

7

29

David Braun

@BraunMDPhD

1 year

In preparation for #ASCO23 ... Before CONTACT-03, for your RCC patients, would you re-challenge with IO (anti-PD-1/PD-L1) after progression on prior IO (anti-PD-1/PD-L1)? @KidneyCancer @DrRanaMcKay @DrChoueiri @montypal @brian_rini @tompowles1 @TiansterZhang @OncoAlert Pls RT

Yes

111

No

203

2

21

29

David Braun

@BraunMDPhD

2 years

Finally, the BraunLab is recruiting! I am looking for smart/innovative/motivated individuals at all levels, interested in cancer immunotherapy/translational research/RCC. Official job postings soon, but for now see: And please RT! @YaleCancer @YaleMed

Join Us — BraunLab

www.thebraunlab.org

3

16

27

David Braun

@BraunMDPhD

4 years

Thank you @DrChoueiri and @AtishChoudhury for the opportunity to speak to this wonderful #LankCenter group!

Toni Choueiri, MD

@DrChoueiri

4 years

Superstar @BraunMDPhD aka “LeBraun” navigating complex integrative analyses of the immune microenvironment in #RCC during #LankCenter #GuSeminars @DanaFarber

2

5

48

2

28

David Braun

@BraunMDPhD

2 years

Congrats to @anotherpathres @shuklasachet @DrChoueiri Dr. Sabina Signoretti and everyone - really highlighting to potential use of molecular features to better identify subsets of tumors responsive to specific therapies.

Scott Haake, MD, PhD

@DrScottHaake

2 years

IMmotion 151 clusters in CM025 interesting. Cluster 4 (high Teff & PDL1) HR with nivo = 0.32-WOW! Angiogenesis clusters 1/2 = no differential benefit to nivo or eve - IO w/o VEGFRi insufficient in these tumors? Cluster 6 trending towards better with eve? #kidneycancer 🧵2/2

0

12

24

1

8

28

David Braun

@BraunMDPhD

2 years

Nothing scarier than being attacked by the @BioLegend Zombie Dyes!!! 😀 Happy Halloween from the #BraunLab !

0

2

28

David Braun

@BraunMDPhD

2 years

While altered metabolism has been investigated in RCC cells, @katy_beckermann with outstanding work highlighting importance of the metabolic environment on TILs/immune response. Are next steps metabolic therapies targeted towards the immune compartment? #IKCSEU22 @KidneyCancer

1

6

27

David Braun

@BraunMDPhD

10 months

Where can biomarkers fit in the RCC field? @VincentWenxinXu with a beautiful discussion and really compelling data for KIM-1 as a useful biomarker in multiple clinical settings in RCC #kcrs23 @kidneycan @OncoAlert @DanaFarber_GU @DanaFarber @harvardmed

0

6

27

David Braun

@BraunMDPhD

2 years

Important work enabling the spatial tracking of specific T cell clonotypes in situ - grateful to be part of the outstanding collaboration

Sophia Liu

@immunoliugy

2 years

Presenting Slide-TCR-seq: our method for measuring the transcriptomes of cells & T cell receptor (TCR) sequences in situ! This collaboration w/ Bryan Iorgulescu, Shuqiang Li, Catherine Wu, and @insitubiology led to some cool findings... 1/8

19

206

808

1

27

David Braun

@BraunMDPhD

4 months

Excellent session led by @katy_beckermann and @bilenma @ASCO #GU24 on variant histologies. And ongoing challenge, but also a call to action for more and better trials.

0

2

26

David Braun

@BraunMDPhD

4 months

Systematic, thorough, nuanced, and balanced discussion by @DrVaishampayan @ASCO #GU24 , highlighting impact of these studies and also the limitations @OncoAlert @kidneycan @KidneyCancer @urotoday

2

14

26

David Braun

@BraunMDPhD

2 years

Thank you for giving me the opportunity to speak about the importance of @CDMRP funding. @YaleCancer @YaleMed

KidneyCAN

@kidneycan

2 years

WATCH to learn more, including examples of @CDMRP #KCRP impact from Andrew Smith of @UABNews and @BraunMDPhD of @YaleMedicine :

1

0

3

0

4

26

David Braun

@BraunMDPhD

3 years

A true landmark for patients with RCC. Hopefully just the beginning of a new era of adjuvant therapy to benefit our patients with RCC! @kidneycan @kcCURE @KidneyCancer

Toni Choueiri, MD

@DrChoueiri

3 years

JUST IN: @US_FDA approves pembrolizumab for adjuvant treatment of RCC at intermediate-high/high risk of recurrence following nephrectomy, or following nephrectomy + resection of metastases. 1st adjuvant immunotherapy in RCC! @DanaFarber @OncoAlert

12

187

554

0

3

26

David Braun

@BraunMDPhD

2 years

Is neoadjuvant therapy safe and efficacious in RCC? Some ongoing trials will begin to give us answers. Wonderful overview and discussion from @TiansterZhang at #IKCSEU22 @KidneyCancer

0

7

26

David Braun

@BraunMDPhD

1 month

An outstanding and comprehensive overview of chromophobe RCC biology by @MVossMD #IKCSEU24 . Please see the recent review for more discussion on the biology of this tumor type in @Cancer_Cell @KidneyCancer

0

7

25

David Braun

@BraunMDPhD

3 years

Grateful to be participating in this great event, and thank you to @JennGuerriero and @MarcoRuella and many others for organizing! #SITC21

Jennifer Guerriero, PhD

@JennGuerriero

3 years

Such a fantastic Day 1 for #sitc21 #sparkathon . An amazing group of early career scientists. The future is very bright. 🤩 Can’t wait for Day 2!

1

3

53

0

1

25

David Braun

@BraunMDPhD

1 year

A fantastic presentation from @TalalZarif1 @DanaFarberNews on an impressive effort to study ICI in a rare GU tumor @ASCO #GU23

1

7

24

David Braun

@BraunMDPhD

3 years

Thank you @NatureMedicine for highlighting our work on this important day #WorldCancerDay . We are working to translate our findings into better treatments for patients with #kidneycancer @DanaFarberNews @harvardmed @broadinstitute

Nature Medicine

@NatureMedicine

3 years

A pooled analysis of tumors from patients with advanced #kidneycancer suggests that response to PD-1 blockade depends on both #Tcell infiltration and enrichment of tumor-intrinsic somatic alterations @DrChoueiri @BraunMDPhD @DanaFarber #WorldCancerDay

1

5

13

0

8

24

David Braun

@BraunMDPhD

4 months

Really nice work from Dr. Saby George @RoswellPark , with @AlbigesL @BourlonMaite and others, looking at subcutaneous nivo administration. Looks very similar to IV in terms of PK, efficacy, safety. Could really change how nivo is delivered in the future @ASCO #GU24

2

12

25

David Braun

@BraunMDPhD

2 years

On Sept. 10, I’ll be riding in the Closer to Free Ride to fundraise for cancer research and care @YaleCancer @SmilowCancer . I will be riding this year in Paris during @myESMO meeting. Please considering donating: Thank you!

My Closer to Free Ride.

The Closer to Free Ride supports patient care and research at Smilow Cancer Hospital and Yale Cancer Center. Learn more today at www.rideclosertofree.org.

www.rideclosertofree.org

1

7

24

David Braun

@BraunMDPhD

10 months

Phenomenal snRNAseq work on translocation RCC from the @srviswanathan lab! #kcrs23 @kidneycan

0

5

23

David Braun

@BraunMDPhD

3 years

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma | NEJM

The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known. In this phase 3, ran...

www.nejm.org

0

5

24

David Braun

@BraunMDPhD

3 years

Important retrospective work from @hannahdzmd @TiansterZhang and others supporting the safety of COVID-19 vaccination in patients with RCC or melanoma #sitc21 @sitcancer @DukeMedSchool

0

7

24

David Braun

@BraunMDPhD

3 years

What is the role of cytoreductive nephrectomy in the context of metastatic ccRCC? Very nice discussion by @DrRanaMcKay , highlighting some prior work from @ZiadBakouny , and an IMPORTANT ongoing trial of RT to the primary (CYTOSHRINK, led by @lalaniMD )

0

9

24

David Braun

@BraunMDPhD

1 year

Very interesting data from B61 study, where response rate for chromophobe RCC is higher than previously seen for an IO-containing regimen @ChungHanLee3 @AlbigesL #ASCO23 @ASCOPost @OncoAlert

1

11

24

David Braun

@BraunMDPhD

10 months

What do cells in the RCC TME eat? Great review of her recent landmark work by @KimrynRathmell , and new insights into TAM recruitment #KCRS23 @kidneycan

0

6

24

David Braun

@BraunMDPhD

2 years

Another proud mentor moment. @ReneeSaliby is an all-star postdoc in the lab working to understand how molecular subtypes of ccRCC might (or might not) help us select the right therapy for each patient, with @DrChoueiri @shuklasachet and many others

KidneyCAN

@kidneycan

2 years

#KCRS22 Oral Abstract Session: @ReneeSaliby @DanaFarber w/ the analysis of molecular clusters from the IMmotion151 trial in the phase 3 JAVELIN Renal 101 trial and in relation to clinical outcomes @BraunMDPhD Abstracts: Register:

0

2

10

1

4

24

David Braun

@BraunMDPhD

2 years

Very thoughtful discussion from Dr. Daniel Geynisman @FoxChaseCancer at #GU22 - a key take home is the need for individualized decision-making, cooperatively with the patient for coming to a decision on adjuvant therapy (and for therapeutic decisions in general!)

0

4

23

David Braun

@BraunMDPhD

3 years

Pretty incredible work from @dbezwada in @RJDLab @UTSWNews investigating mitochondrial function directly from patient tumors (and adjacent non-malignant tissue) #IKCS2021

1

6

23

David Braun

@BraunMDPhD

1 year

Lucky to run into old friends @thenasheffect from our time @IOYIForum #ASCO23

2

3

23

David Braun

@BraunMDPhD

2 years

Quality of life is so important for our patients, but how do we accurately assess this? @crisbergerot presenting important / provocative data: widely used FKSI-19 tool captures symptoms that many patients may not consider relevant. We need better tools! #IKCSEU22 @KidneyCancer

1

9

23

David Braun

@BraunMDPhD

3 years

A huge win for patients with papillary RCC. Wonderful work from @montypal and many others

Neeraj Agarwal, MD, FASCO

@neerajaiims

3 years

#GU21 @ASCO First randomized positive study in papillary metastatic RCC #kidneycancer i.e. @SWOG 1500's results are out: by @montypal @CityofHope_GU @PrimoLaraMD et al 👉"Cabozantinib" is new standard of care for these patients @OncoAlert @urotoday

4

82

170

1

5

22

David Braun

@BraunMDPhD

1 month

Excited to start #IKCSEU24 . First with a bit of history of this beautiful city Sitges @KidneyCancer

0

2

20

David Braun

@BraunMDPhD

3 years

Can you effectively do a randomized trial in non-clear cell / variant histology RCC? YES! SWOG 1500 results presented at #GU21 by @montypal , showing benefit with cabozantib over sunitinib. A huge win for patients with papillary RCC!

0

8

22

David Braun

@BraunMDPhD

6 years

Exciting new study of cabo +/- radium in RCC bone mets #IKCS18

0

4

21

David Braun

@BraunMDPhD

3 years

Extremely nice work. While "recovered" exhausted T cells may resemble memory T cells transcriptionally, they still have the epigenetic "scar" of exhaustion

MoSalah A-Hakeem * (محمد صلاح (بتاع المناعة

@M_S_Hakeem

3 years

Thus, exhaustion leaves durable epigenetic "scars" on Tex constraining future immune responses. These results support epigenetic remodeling interventions for Tex cell targeted immunotherapies. 6/6

0

22

2

22

David Braun

@BraunMDPhD

3 years

Ira Mellman @genentech discussing the importance of the TME. Using an a tumor array platform, his colleagues @genentech were able to show all 3 immune phenotypes starting with same tumor line and with same T cell composition- it's complex interactions in TME that matters #SITC21

0

6

22